This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by St. George, S.
Right arrow Articles by Selitrennikoff, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by St. George, S.
Right arrow Articles by Selitrennikoff, C. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 474-479, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.474-479.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Novel Compounds Active against Leishmania major

Stephanie St. George,1 Jeanette V. Bishop,2 Richard G. Titus,2 and Claude P. Selitrennikoff1*

MycoLogics, Inc, 12635 E. Montview Blvd., Suite 215, Aurora, Colorado 80010,1 Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado 805232

Received 22 August 2005/ Returned for modification 28 September 2005/ Accepted 1 November 2005

Leishmania major is an important trypanosomatid pathogen that causes leishmaniasis, which is a serious disease in much of the Old World. Current treatments include a small number of antimony compounds that, while somewhat effective, are limited by serious side effects. We have screened a small portion of a unique chemical library and have found at least three novel compounds that are effective against L. tarentolae and L. major in vitro and in a murine macrophage model of L. major infection. These compounds were effective in both assays at doses significantly lower than those of sodium stibogluconate (Pentostam) and represent possible candidates for drug development.

* Corresponding author. Mailing address: MycoLogics, Inc., 12635 E. Montview Blvd., Suite 215, Aurora, CO 80010. Phone: (303) 724-3426. Fax: (303) 724-3420. E-mail: Claude.Selitrennikoff{at}uchsc.edu.

Antimicrobial Agents and Chemotherapy, February 2006, p. 474-479, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.474-479.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»